Further data to be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

November 2011

Following Richmond Pharmacology�s Chief Executive Officer and Principal Investigator Dr Jorg Taubel�s presentation at the recent 2nd DIA Cardiac Safety Workshop in Japan, further data will be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), taking place 1st to 3rd December 2011, at Act City Hamamatsu.This year�s annual scientific meeting will assess the latest trends in clinical pharmacology and, as a first, will be jointly hosted by the three societies of the Japanese Society of Clinical Pharmacology and Therapeutics (JPCPT), the Korean Society of Clinical Pharmacology and Therapeutics (KSCPT) and the American Society of Clinical Pharmacology and Therapeutics (ASCPT).Dr Taubel�s poster presentation session will provide an update on the original research carried out by Richmond Pharmacology, and is scheduled for Thursday, 1st December between 14:15 and 15:10:

  • Alternative Methods for the Confirmation of Assay Sensitivity in Thorough QT Studies (Program number: 1-P-77)
  • QT Prolongation in Healthy Japanese Subjects Receiving Moxifloxacin in Thorough QT Studies (Program number: 1-P-78)
  • Sex Differences of the Effect of Moxifloxacin  - A Meta -analysis of Five thorough QT Studies (Program number:  1-P-79)

Our total success rate in all Thorough QT studies reported to date confirms that we are a leading research unit for cardiac safety studies - either as a one stop solution or in conjunction with our preferred partner core labs.For further information on our cardiac safety expertise and other specialist services please speak to a company representative at booth number 5, where we will be available to discuss how Richmond can benefit your prospective Phase I/II study requirements.We look forward to seeing you in Tokyo.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more